ArticleBiotechnology notes (Amsterdam, Netherlands)2022
Synthetic biology landscape in the UK.
Article in Biotechnology notes (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineering biology applications for environmental solutions: potential and challenges.Nature communications · 2025Review
- An integrated engineering worldview of synthetic biology education through the lens of webinar based pedagogy.Frontiers in bioengineering and biotechnology · 2024Article
- Synthetic biology in Indonesia: Potential and projection in a country with mega biodiversity.Biotechnology notes (Amsterdam, Netherlands) · 2023Review
- Bioeconomy in India: Policy, Prospects and Perspective.Engineering biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The UK is home to a vibrant and diverse synthetic biology community. Many of its successes in research innovation and technological commercialisation can be attributed to a strong base of dedicated academics, investors, industrial leadership, and policymakers. Here, we give an overview of the organisations making up the network that have been key to these successes and the roles that they play within the different levels of the community. We start with a brief history of synthetic biology in the UK and continue by describing the progression of the societies and institutions that were set up, with particular focus on the UK's active student and entrepreneurship scene, as well as centres of research. We then contextualise the UK's growing bioeconomy, detailing government trajectories of planned innovation and how these coincide with research translation. The path to commercialisation for researchers is put into comparison to that of the US, the world leader in synthetic biology and its translation, highlighting aspects that differentiate the UK globally. Finally, we conclude with a bright outlook on the current velocity of progress and the state of the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.